project id: TCGA-UCEC; case submitter id: TCGA-AX-A3GI; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 2.0; rna integrity number: 9.7; age at index: 66; days to birth: -24388; ethnicity: not hispanic or latino; gender: female; race: black or african american; vital status: Alive; year of birth: 1945; age at diagnosis: 24388; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 12.0; figo stage: Stage IIIC; icd 10 code: C54.1; last known disease status: not reported; morphology: 8441/3; primary diagnosis: Serous cystadenocarcinoma, NOS; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Endometrium; synchronous malignancy: No; tissue or organ of origin: Endometrium; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 300; initial weight: 110.0; oct embedded: false; preservation method: Unknown; sample id: c5cdb056-0de5-496f-a301-87f11ce50dde; sample submitter id: TCGA-AX-A3GI-01A; portion id: ffe36ec9-c51e-45b3-a992-b06e344ac66a; portion submitter id: TCGA-AX-A3GI-01A-11; slide id: beb03e92-2a77-4b41-a987-7464894843f1; slide submitter id: TCGA-AX-A3GI-01A-01-TSA; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 4.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 2.0; percent tumor cells: 94.0; percent tumor nuclei: 98.0; section location: TOP;